New CEO Alex Snow8 Apr 2022 09:39
About Alex Snow
Alex Snow is an experienced entrepreneur with extensive, executive leadership and a proven track record in AI drug discovery. Alex has a strong background in entrepreneurship and investment in both finance and data driven life science industries. He recently stepped down as Chairman of AI drug discovery company Exscientia prior to its successful $2.6 billion Nasdaq IPO. In 2015 he co-founded Oxford Sciences Innovation Plc (OSI), now called Oxford Science Enterprises, and raised more than GBP600 million to commercialise world-leading science originating at Oxford University. Prior to OSI, Alex spent 20 years in investment banking and fund management, including as CEO of Lansdowne Partners UK LLP, a long-standing shareholder in Sensyne, and as founder and CEO of Evolution Group, a UK mid-market investment banking and wealth management group sold to Investec Bank.